

Formal Appointment of Chair and Directors

Highlights

- Wellnex formally appoints Mr Mario Tascone as Non-executive Chair of Wellnex
- Highly experienced Mr Andrew Vidler and Mr Jeffrey Yeh formally appointed as non-executive directors providing significant industry experience
- Appointments to the board significantly strengthen Wellnex's board following completion of the Pain Away acquisition

Wellnex Life Limited (**Wellnex**, **WNX** or **Company**) (ASX:WNX), a leading consumer healthcare business, is pleased to announce the formal appointment of three highly respected and experienced directors to the board of Wellnex. These appointments will provide invaluable and experience, guidance and increased corporate governance to Wellnex that will drive the Company in building sales and profitability in the growing healthcare and pharmaceutical markets.

Mr Mario Tascone – Non-executive Chair

Mr Tascone has a long history of success in the consumer health and wellness market, serving as Director of Sales and Marketing for Australia's leading pharmacy retailer, Chemist Warehouse. The appointment of Mr Tascone as Chair will provide invaluable expertise as we continue to grow our brands, including the recently acquired leading topical pain relief brand, Pain Away.

Wellnex has a close relationship with Chemist Warehouse, being Wellnex's 6th largest shareholder and the companies having two joint ventures together which will be further be strengthened following the appointment of Mr Tascone as Chair. Mr Tascone currently has no other ASX director roles.

Mr Andrew Vidler – Non-executive director

Mr Vidler has comprehensive experience across retail, consumer health products and retail pharmacy. Andrew's 30 years' experience includes approximately 20 years with the EBOS Group (formerly FH Faulding, Mayne Group and Symbion), where, across several roles, he led the Terry White Chemists and Chemmart pharmacy brands and the Endeavour Consumer Health products business. Mr Vidler is currently Pacific Smiles Group's (PSQ:ASX) Managing Director and Chief Executive Officer. Aside from this role, Mr Vidler has no other ASX director roles.

For the last four years Mr Vidler worked for API Limited (now Wesfarmers Health) where he was responsible for the Priceline retail and Priceline pharmacy businesses.

Mr Vidler has a track record of building strong team cultures while ensuring they stay focused on the marketplace and building customers with an active preference for the products, brands and retailers he oversees.

Mr Jeffrey Yeh – Non-executive director

Mr Yeh is an experienced all-rounded entrepreneur, with over 21 years' experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management.

Mr Yeh co-founded Homart Pharmaceuticals (**Homart**) in 2002, and since then has grown Homart into a premier and award winning manufacturing and brand business with over 200 employees and an international presence. Homart, and its related entities, currently have a 18.3% shareholding in the Company. Mr Yeh currently has no other ASX director roles.

Commenting on the formal appointments of Directors to the Board, Wellnex Chair Mario Tascone said *"I am very pleased to join the board of Wellnex. The company has a great range of 100% owned healthcare brands, strong licensing agreements with Haleon and Arrotex and a growing joint venture partnership with Wagner Liquigesics and SAS-B with Chemist Warehouse. I look forward to working with the board and executive team to leverage these strengths to continue to grow the company and building value for shareholders."*

"I also welcome the formal appointments of fellow Directors Mr Vidler and Mr Yeh. Their appointments gives me complete confidence that Wellnex has the appropriate corporate governance, experience and structure to see the Company through this exciting period."

"Mr Vidler brings significant industry expertise and a long track record of success in the health and pharmaceutical markets whilst Mr Yeh is founder of our trusted and experienced partner in Homart, providing access to our unique and innovative brands into the significant Asian markets."

- ENDS -

This ASX announcement has been authorised by the Board of Wellnex Life Limited (WNX.ASX).

For further information, please contact:

George Karafotias – Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical

companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently agreed to acquire leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/